Rani Therapeutics Holdings, Inc.
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.6M
- Net income
- -$29.7M
- Total assets
- $58.6M
- Market cap
- $93.2M
- Operating margin
- -2346.0%
- Net margin
- -2507.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.6M
- Operating expenses
- $39.9M
- Operating income
- -$38.3M
- Income tax
- $0
- Net income
- -$41.0M
- EPS (basic)
- $-0.45
- EPS (diluted)
- $-0.45
Balance sheet
- Total assets
- $58.6M
- Current assets
- $53.3M
- Total liabilities
- $17.1M
- Current liabilities
- $12.7M
- Shareholders’ equity
- $41.5M
Cash flow
- Operating cash flow
- -$18.7M
- Investing cash flow
- -$7.0M
- Financing cash flow
- $40.3M
- Net cash flow
- $14.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $93.2M
- EPS (diluted)
- $-0.45
- Shares outstanding
- 111.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 30, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $29.7M in FY2025.
- Revenue declined 40% from FY2021 to FY2025.
- Trading 71% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Rani Therapeutics Holdings, Inc..
Write a review
News about Rani Therapeutics Holdings, Inc.
News & sentiment via Polygon.io
